Boston Scientific Q1 sales, profit slightly beat estimates; FY EPS view below estimates

Boston Scientific

22/04/2026 11:40

Overview

Medical technology firm's Q1 revenue grew 12%, slightly beating analyst expectations

Adjusted EPS for Q1 beat analyst expectations

Company completed acquisition of Valencia Technologies and announced positive clinical trial outcomes

Outlook

Boston Scientific sees full-year 2026 net sales growth of 7.0% to 8.5% reported

Company expects 2026 adjusted EPS of $3.34 to $3.41 vs analysts estimate of $3.45

Boston Scientific forecasts Q2 2026 net sales growth of 5.5% to 7.5% reported

Result Drivers

SEGMENT GROWTH - Cardiovascular and Neuromodulation segments saw strong sales increases, with Cardiovascular up 13.5% and Neuromodulation up 17.4% year-over-year

CLINICAL TRIAL RESULTS - Positive trial outcomes for WATCHMAN FLX, EKOS, and FARAPULSE devices highlighted as supporting product differentiation

REGIONAL SALES - Sales growth was strongest in Latin America (19% reported) and Asia-Pacific (14.7% reported), with U.S. and EMEA also posting increases

Company press release: ID:nPn6357qka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
$5.20 bln
$5.17 bln (25 Analysts)
Q1 Adjusted EPS
Beat
$0.80
$0.79 (25 Analysts)
Q1 EPS
$0.90
Q1 Net Income
$1.34 bln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 34 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Boston Scientific Corp is $98.50, about 65.5% above its April 21 closing price of $59.52

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 27 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)